The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England

Abstract

The safety of the atypical antipsychotic quetiapine as used in general practice in England was examined by prescription-event monitoring (PEM). Patients were identified from dispensed National Health Service (NHS) prescriptions issued by general practitioners (GPs) for quetiapine between October 1997 and July 1999. The outcome data were event reports obtained by sending questionnaires (`green forms') to the prescribing doctor at Least 6 months after the first prescription for an individual patient.

Green forms with clinically usefuL information on 1728 patients (median age 39 years (IQR 30—56); 53% female) were received. The most frequently reported event during the first month of treatment was `drowsiness/sedation' (47; 3% cohort). This was also the most frequently reported specified adverse drug reaction (ADR) to quetiapine (7; 11% of 65 reported ADRs) and the highest reported clinical reason for stopping quetiapine (51; 6% of the 734 reported reasons for stopping).

There was a Low incidence of extrapyramidal disease (21 during treatment, 1% of cohort) and hyperprolactinaemia (three during treatment, 0.2%) in this study. Three cases of diabetes mellitus in this cohort were reported to be a new diagnosis.

Six pregnancies were reported during treatment with quetiapine, five of which were exposed during the first trimester only. There were four Live births with no reported congenital abnormaLities.

Fifty-six deaths were reported during this study (3% cohort). The most frequently reported causes of death reLated to the cardiovascular (18) and respiratory (15) systems.

The results of this post-marketing surveillance study demonstrated that quetiapine is generally well-tolerated when used in general practice.

Keywords

atypical antipsychotic quetiapine prescription-event monitoring (PEM)extrapyramidal disease pregnancy outcome

Get full access to this article

View all access options for this article.

References

Ananth J. , Parameswaran S. , Hara, B. (2004) Drug therapy in schizophrenia . Curr Pharm Design 10: 2205—2217

Arvanitis L. , Miller B.G. (1997) Multiple fixed doses of `Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group . Biol Psychiatry 42: 233—246

Astra Zeneca (2005) Summary of product characteristics `Seroquel'. June

Borison R. , Arvantits L.A. , Miller B.G. (1996) ICI 204,636, an atypical antipsychotic: effectiveness and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group . J Clin Psychopharmacol 16: 158—169

Buckley P. (2004) Effectiveness of quetiapine for the treatment of schizophrenia: a combined analysis of three-placebo controlled trials . Curr Med Res Opin 20: 1357—1363

Cioms/Who (2002) International ethical guidelines for biomedical research involving human subjects. CIOMS/WHO , Geneva

College of Physicians (1996) Guidelines on the practice of ethics committees in medical research involving human subjects. Royal College of Physicians, London

Committee of Safety of Medicines (2004) Aytpical antipsychotic drugs and stroke: message from Professor Gordon Duff, chairman, Committee on Safety of Medicines .

Dev V. , Raniwalla J. (2000) Quetiapine. A review of its safety in the management of schizophrenia . Drug Safety 23: 295—307

10.

Friedman J.H. (2003) Atypical antipsychotics in the EPS-vulnerable patient . Psychoneuroendocrinology 28: 39—51

11.

Goldstein J. , Cantillon M. (1999) Low incidence of reproductive/hormonal side effects with Seroquel (quetiapine) is supported by its lack of elevation of plasma prolactin levels . Int J Neuropsychopharmacol 12: s118

12.

Jeste D.V. , Caligiuri M.P. , Paulsen J.S. , Heaton R.K. , Lacro J.P. , Harris M.J. , Bailey A. , Fell R.L. , McAdams R.A. (1995) Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients . Arch Gen Psychiatry 52: 756

13.

Layton D. , Harris S. , Wilton L. , Shakir S A W (2005) Comparison of the incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine and olanzapine in general practice in England including patients with dementia . J Psychopharmacol 19: 473—482

14.

McAvoy B. , Kramer E. (1996) General practice postal surveys: a questionnaire too far? BMJ 33: 732—733

15.

Martin R.M. , Kapoor K.V. , Wilton L.V. , Mann R.D. (1998) Underreporting of suspected adverse drug reactions to newly marketed drugs in general practice . BMJ 317: 119—120

16.

Meats P. (1997) Quetiapine (SeroquelTM); an effective and well-tolerated atypical antipsychotic . Int J Psych Clin 1: 231—239

17.

Motsinger C. , Perron G. , Lacy T. ( 2003) Use of atypical drugs in patients with dementia . American Family Physican 67: 2335—2340

18.

Multi-Centre Research Ethics Committees Guidance Notes (2000) Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary, Appendix C; 21

19.

Nice (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia . Technology Appraisal Guidance 43

20.

Sartorius T. , Goldberg D. , Tantam D. (1991) The public health impact of mental disorders. In Holland W , Detels R , Knox G (eds), Oxford Textbook of Public Health. Oxford University Press , London , pp. 268—269

21.

Schwenkreis P. , Assion H-J. (2004) Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 5: 73—82 .

22.

Shakir S. (2004) Causality and correlation in pharmacovigilance . In Talbot J , Waller P (eds) Stephen's Detection of New Adverse Drug Reactions . John Wiley, Chichester

23.

Shakir S. (2005) Prescription-event monitoring. In Strom B (ed.) Pharmacoepidemiology. Chichester: John Wiley

24.

Stigler K.A. , Potenza M.N. , Posey D.J. , McDougle C.J. (2004) Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance and management . Paediatric Drugs 6: 33—44

25.

Wetterling T. (2001) Bodyweight gain with atypical antipsychotics. A comparative Review . Drug Safety 24: 59—73 .

26.

Wozniak K. , Linnoila M. (1991) Hyperglycaemic properties of serotonin receptor antagonists . Life Sci 49: 101—109

27.

Yamada J. , Sugimoto Y. , Yoshikawa T. , Kimura I. , Horisaka K. (1995) The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycaemia in rats . Life Sci 57: 819—825